Effect of Local Anesthetic EMLA (Lidocaine 2.5% and Prilocaine 2.5%) Cream and Reduction in Dose, Pain and Intravenous Analgesic During Permanent Pacemaker Implantation

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02016976

Enrollment

Registered

2013-12-20

Start date

2014-01-31

Completion date

2014-08-31

Last updated

2013-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pacemaker Implantation, Pain

Brief summary

The investigators believe that the local anesthetic EMLA (Lidocaine 2.5% and Prilocaine 2.5%) cream will lessen pain and reduce the need for anesthesia and analgesia, when implanting a permanent pacemaker.

Interventions

DRUGEMLA Analgesic Cream

DRUGDormicum 2.5 mg and Pethidine 25 mg

Routine anesthesia and analgesia ( Dormicum 2.5 mg and Pethidine 25 mg )normally given to patients before and during pacemaker implantation

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All patients undergoing pacemaker implantation

Exclusion criteria

* Dementia Patients * Psychiatric Patients * Unconscious Patients * Patients with sensitivity to EMLA

Design outcomes

Primary

Measure	Time frame	Description
Pain reduction	One hour	EMLA anesthetic cream will be applied to area where pacemaker is to be implanted. Pain reduction will be measured using the visual analog scale (VAS) at three intervals.

Countries

Israel

Contacts

Primary ContactAnat Glass, RN, MA

anatglass1@gmail.com972-52-8335558

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026